Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02494713 · ClinicalTrials.gov registry record · Phase 2
Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.
- Terminated
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
NCT02494713 is a Phase 2 study that was terminated before completion, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 4 participants.
The verdict
NCT02494713, a Phase 2 study, was terminated before completion, sponsored by The University of Texas Health Science Center, Houston.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
Study Summary
This is a study for men who have locally-advanced prostate cancer and are eligible to undergo prostatectomy. Standard treatment is prostatectomy alone, but there is a chance that cancer may spread to other organs in the future, even after the prostate is removed. If this were to occur, standard treatment would be androgen deprivation therapy (ADT; hormone therapy that blocks testosterone) plus chemotherapy. Clinical trials suggest that neoadjuvant treatment (treatment given before primary therapy) may prevent a recurrence. The purpose of this research study is to assess the safety and benefit of ADT plus chemotherapy given before prostate removal.
Interventions
- DRUG Docetaxel
- DRUG Doxorubicin
- DRUG Degarelix
- DRUG Ketoconazole
- DRUG Estramustine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-09-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02494713
The ClinicalTrials.gov registry entry for NCT02494713 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Docetaxel is the first listed.
NCT02494713 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02494713 about?
NCT02494713 is a clinical study titled "Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer". This is a study for men who have locally-advanced prostate cancer and are eligible to undergo prostatectomy. Standard treatment is prostatectomy alone, but there is a chance that cancer may spread to other organs in the future, even after the prostate is removed. If this were to occur, standard trea...
What is the current status of trial NCT02494713?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2015-10. Estimated completion is 2017-09-14.
What interventions are being tested in trial NCT02494713?
The interventions under investigation include: Docetaxel (DRUG), Doxorubicin (DRUG), Degarelix (DRUG), Ketoconazole (DRUG), Estramustine (DRUG).
Who is sponsoring clinical trial NCT02494713?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.